Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.
Yvette MeißnerMartin SchaeferKatinka AlbrechtJoern KekowSilke ZinkeHans-Peter TonyAnja StrangfeldPublished in: RMD open (2023)
In this German observational cohort study, MACE did not occur more frequently with JAKi compared with other DMARDs. However, individual JAKis showed different unadjusted IRs.